AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Thyrotropin-releasing hormone-degrading ectoenzyme

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UKU6

UPID:

TRHDE_HUMAN

Alternative names:

Pyroglutamyl-peptidase II; TRH-specific aminopeptidase; Thyroliberinase

Alternative UPACC:

Q9UKU6; A5PL19; Q6UWJ4

Background:

The Thyrotropin-releasing hormone-degrading ectoenzyme, also known as Pyroglutamyl-peptidase II, TRH-specific aminopeptidase, or Thyroliberinase, plays a crucial role in the specific inactivation of TRH after its release. This protein is encoded by the gene with the accession number Q9UKU6.

Therapeutic significance:

Understanding the role of Thyrotropin-releasing hormone-degrading ectoenzyme could open doors to potential therapeutic strategies. Its precise function in regulating TRH, a critical hormone in the thyroid axis, suggests its involvement in maintaining hormonal balance and metabolic health.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.